SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-020979
Filing Date
2021-08-23
Accepted
2021-08-23 15:05:52
Documents
63
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1282277
2 ex31-1.htm EX-31.1 10372
3 ex32-1.htm EX-32.1 5954
  Complete submission text file 0001493152-21-020979.txt   5568290

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT endv-20210630.xsd EX-101.SCH 50686
5 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT endv-20210630_cal.xml EX-101.CAL 50665
6 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT endv-20210630_def.xml EX-101.DEF 212714
7 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT endv-20210630_lab.xml EX-101.LAB 409229
8 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT endv-20210630_pre.xml EX-101.PRE 298307
9 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 742643
Mailing Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367
Business Address 6320 CANOGA AVENUE 15TH FLOOR WOODLAND HILLS CA 91367 (800) 489-4774
ENDONOVO THERAPEUTICS, INC. (Filer) CIK: 0001528172 (see all company filings)

IRS No.: 452552528 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-55453 | Film No.: 211196573
SIC: 2834 Pharmaceutical Preparations